Abstract 5160
Background
The Irish Cancer Society is committed to monitoring the impact of our Cancer Information Services (CIS) at 4 key stages (prevention, support, survivorship and palliative) to demonstrate the positive changes our services bring to the people affected by cancer. CIS incorporates Cancer Nurseline (freephone cancer helpline) and Daffodil Centres (walkin cancer information and support centres) based in cancer centres. Both are staffed by specialist cancer nurses. CIS provides support, advice and information to anyone affected by cancer. The information provided is tailored to the needs of each individual enquirer giving them greater access to cancer support and information which complements the service provided by the clinical teams in hospitals or in the community. In 2018 there were 47371 contacts to the service.
Methods
Impact Monitoring uses surveys (paper and online) to collect information from service users. The nurses recruited cancer support enquirers over a two month period during September and October 2018. An enquirers’ distress level was assessed (using distress screening) by the nurse to determine if they were suitable to take part in the survey. Consent was obtained from participants across all services. Returned surveys were entered into a database and analysed according to themes and patterns. All respondents were anonymous.
Results
CIS had many positive impacts. Enquirers to the service appreciated the opportunity to access information from a healthcare professional either by phone or within a Daffodil Centre. During analysis some of the main benefits of the service identified include • Increased knowledge of cancer and its symptoms • More supported and aware of emotional supports • More in control • Reduced anxiety. Accurate and reliable information from a CIS healthcare professional offered reassurance to patients.
Conclusions
Having access to a cancer nurse through the CIS gave cancer patients the opportunity to avail of support, information and advice as and when they needed it. Enquirers felt they could talk through their questions and concerns, with the nurse providing information and guidance which reassured them. Talking to a nurse helped people feel more supported, more knowledgeable about their cancer and hopeful about the future.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2507 - KEYLYNK-010: Phase 3 Study of Pembrolizumab (pembro) Plus Olaparib (OLA) vs Enzalutamide (ENZA) or Abiraterone (ABI) in ENZA- or ABI-Pretreated Patients (pts) With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Had Progression on Chemotherapy (CTx)
Presenter: Evan Yu
Session: Poster Display session 3
Resources:
Abstract
2944 - PROSTRATEGY: A Spanish Genitourinary Oncology Group (SOGUG) multi-arm multistage (MAMS) phase III trial of immunotherapy strategies in high-volume metastasic hormone-sensitive prostate cancer.
Presenter: Jose Arranz Arija
Session: Poster Display session 3
Resources:
Abstract
3535 - A phase 1 study of AMG 160, a half-life extended bispecific T cell engager (HLE BiTE) immuno-oncology therapy targeting PSMA, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Ben Tran
Session: Poster Display session 3
Resources:
Abstract
4951 - ProBio: An outcome-adaptive, multi-arm, open-label, multiple assignment randomised controlled biomarker-driven trial in patients with metastatic castration-resistant prostate cancer (EudraCT: 2018-002350-78, NCT03903835)
Presenter: Johan Lindberg
Session: Poster Display session 3
Resources:
Abstract
2892 - A phase 3 randomized, placebo-controlled, double-blind study of niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in patients with metastatic prostate cancer (NCT03748641)
Presenter: Kim Chi
Session: Poster Display session 3
Resources:
Abstract
2427 - The Extended/Phase II Study of Safety And Tolerability Of Proxalutamide (GT0918) In Subjects With Metastatic Castrate Resistant Prostate Cancer (mCRPC) Who Failed Either Abiraterone (Abi) Or Enzalutamide (Enza)
Presenter: Nicholas Vogelzang
Session: Poster Display session 3
Resources:
Abstract
3224 - Addition of an oral docetaxel treatment (ModraDoc006/r) to androgen deprivation therapy (ADT) and intensity-modulated radiation therapy (IMRT) in patients with high risk N+M0 prostate cancer
Presenter: Marit Vermunt
Session: Poster Display session 3
Resources:
Abstract
3312 - A phase II randomized, open-label study comparing salvage radiotherapy in combination with 6 months of androgen-deprivation therapy with LHRH agonist or antagonist versus anti-androgen therapy with apalutamide in patients with biochemical progression after radical prostatectomy.
Presenter: Piet Dirix
Session: Poster Display session 3
Resources:
Abstract
2829 - Health-Related Quality of Life (HRQoL) and Updated Follow-Up From KEYNOTE-057: Phase 2 Study of Pembrolizumab (pembro) for Patients (pts) With High-Risk (HR) Non–Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guérin (BCG)
Presenter: Ronald de Wit
Session: Poster Display session 3
Resources:
Abstract
2673 - Clinical activity of vofatamab (V), an FGFR3 selective antibody in combination with pembrolizumab (P) in metastatic urothelial carcinoma (mUC), updated interim analysis of FIERCE-22
Presenter: Arlene Siefker-Radtke
Session: Poster Display session 3
Resources:
Abstract